Evidence map›Paper›PMID 34024063›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2021

[Progress in Single-cell RNA Sequencing of Lung Adenocarcinoma].

Yichu Lin, Donglai Chen, Qifeng Ding, Xuejuan Zhu, Rongying Zhu, Yongbing Chen

Abstract readReview
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yichu LinDepartment of Thoracic Surgery, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
Donglai ChenDepartment of 
Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China.
Qifeng DingDepartment of Thoracic Surgery, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
Xuejuan ZhuDepartment of Thoracic Surgery, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
Rongying ZhuDepartment of Thoracic Surgery, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
Yongbing ChenDepartment of Thoracic Surgery, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer and one of the main causes of cancer-related deaths. In the past decade, with the widespread use of computed tomography (CT) in routine screening for lung cancer, the incidence of LUAD presenting as small pulmonary nodules radiologically, has increased remarkably. The mechanisms of the occurrence and progression of LUADs are complex, and the prognoses of patients with LUAD vary significantly. Although significant progress has been made in targeted therapy and immunotherapy for LUADs in recent years, the drug resistance of tumor cells has not been effectively overcome, which limits the benefits of patients. With the accomplishment of the Human Genome Project, sequencing-based genomic and transcriptomics have come into the field of clinical and scientific researches. Single-cell sequencing, as a new type of sequencing method that has captured increasing attention recently, can perform specific analysis of cell populations at single-cell level, which can reveal the unique changes of each cell type. Single-cell sequencing can also provide accurate assessment on heterogeneous stromal cells and cancer cells, which is helpful to reveal the complexity of molecular compositions and differences between non- and malignant tissues. To sum up, it is an urgent need for clinicians and basic scientists to deeply understand the pathogenesis and development of LUAD, the heterogeneity of tumor microenvironment (TME) and the mechanism of drug resistance formation through single-cell sequencing, so as to discover new therapeutic targets. In this paper, we reviewed and summarized the application and progress in single-cell sequencing of LUADs.
.

Indexed as

Adenocarcinoma of LungLung NeoplasmsSequence Analysis, RNADrug Resistance, NeoplasmHumansPrognosisTumor MicroenvironmentDrug resistanceLung neoplasmsProgressionSingle-cell sequencing

Identifiers

PMID34024063
PMCPMC8246394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.